Laboratory and clinical studies on cefclidin

We performed a laboratory and clinical evaluation of cefclidin (CFCL), a new parenteral cephalosporin, with the following results. 1) Antimicrobial activity The minimum inhibitory concentrations (MICs) of CFCL for a total of 307 clinically isolated strains, were determined and compared with those of Piperacillin, ceftazidime, cefuzonam and ceftizoxime, using MIC2000. CFCL had wide antimicrobial activities to the clinically isolated strains except MSSA, and MRSA. In particular, CFCL had better MICs than another compared antimicrobial agents. 2) Clinical efficacy CFCL 1g/day or 2g/day was given to 6 patients with bacterial pneumonia, 7 patient with chronic bronchitis, 1 patient with bacterial infection complicated with bronchiectasis, and 1 patient with bacterial infection complicated with lung fibrosis, for 4 to 91 days. Clinical responses were excellent in 2 patients, good in 9 patients, fair in 1 patient, not effective in 2 patients, and not evaluated in one patient. Clinical efficacy was 79%. Side effects, including the elevation of intraocular pressure, were not observed in any patients. Elevation of eosinophile was observed in 1 case.